Redeye has revised its estimates in light of Heliospectra’s Q4 2023 report, which was slightly softer than expected regarding sales and order intake. Yet, we expect a rebound in the Dutch market during 2024 and expect Heliospect to capitalise on it with its new product platform. However, due to softer-than-expected order intake in Q4 2023 and seasonal effects, we foresee a softer first half followed by a stronger second half in 2024. Our Base case remains intact at SEK1.4 per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Heliospectra - Rebound in the Duch market boosts strong growth potential

© Modular Finance, source Nordic Press Releases